Janux Therapeutics, Inc.
JANX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$24,313 | -$33,858 | -$23,508 | -$20,216 |
| Dep. & Amort. | $501 | $541 | $519 | $512 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $9,044 | $10,960 | $10,702 | $6,251 |
| Change in WC | $6,535 | $3,750 | -$516 | -$345 |
| Other Non-Cash | -$4,623 | -$5,206 | -$4,221 | -$2,927 |
| Operating Cash Flow | -$12,856 | -$23,813 | -$17,024 | -$16,725 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$93 | -$473 | -$371 | -$42 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$117,969 | -$92,685 | -$371,291 | -$24,032 |
| Inv. Sales/Matur. | $126,368 | $94,720 | $31,270 | $58,000 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | $8,306 | $1,562 | -$340,392 | $33,926 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $0 | $954 | $554 | $378,208 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $493 | $0 | $0 | $8,442 |
| Financing Cash Flow | $493 | $954 | $554 | $386,650 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$4,057 | -$21,297 | -$356,862 | $403,851 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $53,262 | $74,559 | $430,605 | $27,570 |
| End Cash | $49,205 | $53,262 | $73,743 | $431,421 |
| Free Cash Flow | -$12,949 | -$24,286 | -$17,395 | -$16,767 |